I had already read elsewhere that zerumbone suppresses the activation of constitutive NF-kappaB ("constitutive" essentially means “active all the time,” which is a BAD thing, see my page on Nuclear Factor-kappaB for details), thus preventing a lot of nasty things from happening. The abstract tells us that it also suppresses, just to give a few better known (to me, anyway) examples, COX-2, Bcl-2 and the Epstein-Barr virus, AND it potentiates the killing effect of chemotherapy on cancer cells. So far, so good.
The full study begins with Hippocrates’ famous “Let food be thy medicine and medicine be thy food.” The study then provides a quick account of zerumbone that was first isolated in 1956 from the essential oil of rhizomes of a wild ginger, Zingiber zerumbet Smith, which is widespread in Southeast Asia.
Only about 40 years later, beginning in the 1990s, did it get the attention it deserved, though, as the following excerpts prove: zerumbone has been found to suppress the proliferation of colon cancer and breast cancer, with minimal effects on normal cells. Zerumbone has also been shown to suppress inflammation, suppress the initiation and promotion of skin tumors in mice, etc. Boy, this could easily turn into a sort of cancer “laundry list”! Ok, let me read on and do my best to avoid any mentions of laundry (of which I have been doing tons since we got home from our wonderful holiday…!).
Let’s see. On the one hand, zerumbone is a very potent inhibitor of TNF-induced NF-kB activation. TNF stands for tumour necrosis factor, by the way (hmmm, this is a rather complicated topic that I may address at some point, but for now let it suffice that in this particular scenario, that is, by activating NF-kB, TNF behaves badly, a bit like Mr. Hyde). Anyway, this plant extract suppresses TNF-induced invasion activity, which means it can block tumour metastasis…in vitro at least. I also found it interesting that cells pretreated with zerumbone showed no activation of NF-kB, even after 60 min of TNF stimulation. No activation of NF-kappaB. Extraordinary, no?
On the other hand, zerumbone increased the killing effect of TNF (this time, in its Dr. Jekyll role) on cancer cells by blocking NF-kB. See, I told you it was complicated! Okay, forget this entire part…for now, at least! I will jump to the Discussion section of the study.
The purpose of the study was to see if the antiinflammatory and antiproliferative effects of zerumbone were mediated through modulation of NF-kB and NF-kB regulated gene products involved in inflammation, proliferation, and apoptosis. The researchers found that zerumbone suppressed NF-kB activation induced by various carcinogens and inflammatory agents irrespective of cell type. Super duper.
There are heaps of details in this study, and I confess that I avoided listing them here as much as possible since they were of as much interest to me as a report on the newest most fashionable hair style/colour (yawn!), and I very much doubt they would have grabbed the attention of more than a few of you. However, I would be glad to forward the full study to those of you who enjoy reading about hetarodimers, IkappaBalpha phosphorylation (also suppressed by zerumbone, by the way) and annexing V staining…
Well, okay, here are a few details for the detail-hungry readers: in addition to inhibiting NF-kB (etc.), zerumbone downregulated NF-kB dependent gene products involved in cell proliferation (e.g. cyclin D1 and c-Myc), in antiapoptosis (e.g. survivin, IAP1, IAP2, XIAP, Bcl-2, Bcl-xL, Bfl-1/A1, and FLIP), and in invasion (MMP-9, COX-2, and ICAM-1). Now, aren’t you GLAD I spared you most of the details?
I was interested to see that zerumbone also inhibits MMP-9 (so does thalidomide, by the way, if I am not mistaken), or matrix metallopeptidase 9. I have written on previous occasions about this human enzyme that of course is involved, and not at all in a positive way!, in myeloma (see for instance: http://tinyurl.com/3w54k8) and angiogenesis.
The study concludes: On the basis of our findings, we conclude that zerumbone is a potent inhibitor of NF-kB and NF-kB-regulated gene products and that this inhibition may explain its antiproliferative and antiinflammatory effects.
Here we have another substance that shows tremendous potential in the lab…but, okay, it’s a bit early to get overly excited, since zerumbone is not easy to obtain, and besides, it also would appear to cost an arm and a leg (I received an actual quote from a lab…mamma mia, quanto costa!!!). Drat!
So, given these obstacles, you may rightly ask me: what’s the point of researching and writing about any of these substances that have strong anticancer effects in vitro but are not being tested outside a lab setting?
Well, my main purpose is to get the word out via my blog.
You see, I believe that we can do something to change the current situation, in which promising anticancer plant extracts are essentially being ignored (for obvious reasons, just think of “Sicko”…).
One small and easy thing that we can all do is take the studies about zerumbone (or a substance of your choice, just take your pick among my Pages, e.g.) to our doctors and try to spark their curiosity.
Here, I hope, is an encouraging example. Out of curiosity this morning I did a search for “curcumin and cancer" on PubMed, where I found a total of 806 studies. Now, what follows may not be very scientific, but it does show how the interest in curcumin has been rising throughout the years.
In 2001 there were 41 studies on curcumin and cancer. Last year there were 129. And right now, that is, just a few months into 2008, there are already 48 studies. Astonishing, no?
The irrepressible optimist in me is convinced that we (cancer patients and/or curcumin-takers in general) have a lot to do with this change.
So if we can get just one doctor interested in zerumbone or cyclopamine or DMAPT or another plant extract…even just one doctor…